North America Pharmacogenomics Market By Technology (Sequencing, Polymerase Chain Reaction, Electrophoresis, Mass Spectrometry, Microarray and Others), By Application (Oncology, Psychiatry, Infectious Diseases, Neurological Diseases, Pain management, Cardiovascular Diseases and Others), By End User (Hospitals and Clinics, Research Institutions, and Academic Institutes)

Analysis of Market Size & Trends

The North America Pharmacogenomics Market would witness market growth of 8.1% CAGR during the forecast period (2019-2025). Pharmacogenomics is helpful in treating cancer and has improved the patient survival rate, along with reducing the unnecessary cost due to unresponsive treatment by patients. Therefore, pharmacogenomics for cancer therapy has created multiple crucial discoveries in the existing cancer treatment; thereby, driving the market growth over the forecast period. The growing expenditure in R&D and increasing rate of adverse reactions have augmented the adoption of pharmacogenomics across the globe. Also, there is a significant increase in the number of research studies which are related to next-generation sequencing. This is expected to increase the demand for pharmacogenomic tests in the future.

Technological advancements along with molecular diagnostics procedure to better understand the genetic structure of the individual patients is expected to further boost the growth of pharmacogenomics market over the forecast period.

Based on Technology, the market is segmented into Sequencing, Polymerase Chain Reaction, Electrophoresis, Mass Spectrometry, Microarray and Others. Based on Application, the market is segmented into Oncology, Psychiatry, Infectious Diseases, Neurological Diseases, Pain management, Cardiovascular Diseases and Others. Based on End User, the market is segmented into Hospitals and Clinics, Research Institutions, and Academic Institutes. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

Click Here For Free Insights

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Empire Genomics LLC, Illumina, Inc., oneome LLC, Myriad Genetics Inc., Thermo Fisher Scientific, Inc., Teva Pharmaceuticals Industries Ltd., Bayer AG, Opko Health, Inc., and Becton, Dickinson and Company.

Scope of the Pharmacogenomics Market Analysis

Market Segmentation:

By Technology

• Sequencing
• Polymerase Chain Reaction
• Electrophoresis
• Mass Spectrometry
• Microarray
• Others

By Application

• Oncology
• Psychiatry
• Infectious Diseases
• Neurological Diseases
• Pain management
• Cardiovascular Diseases
• Others

By End User

• Hospitals and Clinics
• Research Institutions
• Academic Institutes

By Country

• US
• Canada
• Mexico
• Rest of North America

Companies Profiled

• Abbott Laboratories
• Empire Genomics LLC
• Illumina, Inc.
• OneOme LLC
• Myriad Genetics Inc.
• Thermo Fisher Scientific, Inc.
• Teva Pharmaceuticals Industries Ltd.
• Bayer AG
• Opko Health, Inc.
• Becton, Dickinson and Company